We are committed to building a pipeline for our highly selective aldosterone synthase inhibitor (CIN-107) to bring safe and effective treatment to patients with currently unmet needs.
About Treatment-Resistant Hypertension
Treatment-resistant hypertension (rHTN) is usually diagnosed when a person’s hypertension medications are no longer helping lower his or her blood pressure.
One potential cause of treatment-resistant hypertension is a build-up of a chemical called aldosterone, which helps regulate blood pressure. Many hypertension medications are designed to lower the amount of aldosterone in the body. However, aldosterone levels can sometimes increase even if you are taking medications to reduce it. This makes it difficult to control blood pressure.
The study drug is designed to work with your current medications to reduce aldosterone.
To learn more about our clinical research study, visit https://brightnstudy.com/.
About Primary Aldosteronism
Primary aldosteronism (PA) is a condition caused by overactive adrenal glands, causing the body to create too much of a hormone called aldosterone. This hormone helps the body manage the amount of sodium and potassium in the body.
When aldosterone increases, your body holds on to more water, causing blood pressure to go up.
Ongoing Clinical Trials
We are currently evaluating CIN-107 in two Phase 2 studies for treatment-resistant hypertension and primary aldosteronism.
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of 3 Doses of CIN-107 as Compared to Placebo After 12 Weeks of Treatment in Patients With Treatment-Resistant Hypertension
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of CIN-107 for the Treatment of Patients With Primary Aldosteronism
To learn more about our clinical study of CIN-107, visit www.ClinicalTrials.gov.